I'M PROBABLY TOO EARLY BUT I'M PUTTING MONEY TO WORK TODAY SO WHY NOT. PUT THIS AWAY FOR A YEAR AND WE'LL TALK. TripAdvisor (TRIP) Shares of TripAdvisor are trading at a forward P/E of 12.1X. TRIP also has a PEG Ratio of 0.7, a Price/Cash Flow ratio of 20.7X, and a Price/Sales ratio of 1.6X. Value investors don't just pay attention to a company's valuation ratios; positive earnings play a crucial role, too. Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2023. The Zacks Consensus Estimate has increased $0.02 to $1.13 per share. TRIP has an average earnings surprise of 71.7%.
I'M NOT QUITE READY TO GO HERE NOW-BUT FEEL THE SAME WAY ABOUT CFLT. CONFLUENT. VERY IN THE DUMPS. SHOULD BE MATERIALLY HIGHER AFTER A YEAR - Confluent, Inc. (CFLT) 52 WEEK H- $41 NasdaqGS - NasdaqGS Real Time Price. 22.30-0.30(-1.31%) As of 11:57AM EST.
09:00 AM ET 01/17/2024 Monday.com(MNDY) is just above a buy point in a cup base, according to IBD MNDY stock is today's selection for IBD 50 Stocks To Watch. Shares gapped up and retook their 10-week moving average in strong volume after third-quarter results came out Nov. 13. The stock then broke out to new highs soon after Monday.com held its investor day in early December. The stock retreated after that, but found support at the 50-day moving average. Today, it is just above a buy zone from the 185.81 handle buy point to 195.10. In addition, 198.15 acts as an alternative entry. Monday.com listed on the Nasdaq at an initial price of 155 per share in June 2021. Among its investors,Salesforce's(CRM) venture wing purchased$75 millionof the stock in a private placement even as the stock started trading. Shares popped on the first day of trading and reached an all-time high of 450 in November 2021. In 2023, the enterprise software stock rose 54% versus the S&P 500's 24% gain. TWO THOUGHTS: SUCH A HIGH PRICED IPO $155 TELLS US SOMETHING. SALESFORCE ONE DAY COULD CASH OUT.
Piper Sandler believes inventory/sales spreads are finally largely under control Discussing the 2024 outlook for global lifestyle brands, retail and digital disruptors, Piper Sandler said it believes the most important swing factor will be whether there will be a shift back to discretionary goods. Both Walmart(WMT)and Target(TGT)have been clear that a shift to more discretionary items would drive a favorable margin mix. The firm is inclined to be constructive on this point -- assuming that consumer spending remains stable -- arguing that disinflation and deflation and more moderate experiential spend could drive a wallet share shift to discretionary purchases. Piper Sandler remains Overweight on both big box retailers, and upgrades Revolve Group(RVLV)and Burlington Stores(BURL). Within its coverage, the firm's favorite 2024 ideas are Target, Revolve, and Warby Parker(WRBY).
GigaCloud Technology Inc. (GCT)-- THIS CAME UP RECENTLY.... NasdaqGM - NasdaqGM Real Time Price. As of 12:10PM EST.
THIS POOR STOCK Toast, Inc. (TOST) NYSE - Nasdaq Real Time Price. 16.85-0.44(-2.57%) As of 12:12PM EST.
-> Toast: Solving pain points in a huge global industry Toast has a simple but compelling model of automated hardware and software tools for the restaurant industry. It offers a range of products and services to fit various needs in this niche with everything a restaurant needs to operate, including point-of-sale devices, self-ordering kiosks, payment processing, and online ordering, plus services like marketing and loyalty programs. Management believes Toast's competitive edge lies in both its comprehensive offerings and the fact they're purpose-built for the restaurant industry. In the third quarter, it added 25,000 new locations from the year-ago period for a total of 99,000, and it sees a serviceable addressable market of $15 billion. Annualized recurring revenue (ARR) was $1.2 billion in the third quarter, a 40% increase year over year. Despite this rapid growth, Toast stock is down 16% over the past year. The company is still posting losses, but its bottom line is improving. Net losses narrowed from $98 million last year to $31 million in the latest quarter, and gross profit increased 50% to $226 million. At the current price, Toast stock trades at a cheap valuation, just 2.6 times trailing-12-month sales. As the top and bottom lines continue to rise, Toast could be a standout stock this year.
I DON'T REALLY HAVE THE ENERGY TO FIGURE THIS OUT NOW. Adagene Inc. (ADAG)- STK WAS $2 SOMETHING IN JAN AND SPIKED AND NOW IS CRASHING ON WHAT INITIALLY READS AS OK NEWS. NasdaqGM - NasdaqGM Real Time Price. 2.0700-1.7300 (-45.53%) As of 12:14PM EST. Market open. COULD BE A SERIOUS BOUNCE BACK CANDIDATE BUT I ALREADY HAVE ONE OF THOSE SORT OF STORIES GOING WITH CHECKPOINT //
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) PR Newswire Wed, January 17, 2024, 7:00 AM EST·6 min read In this article: ADAG -43.6842% Watchlist Pattern Bullish - Data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more frequent and repeat doses of the anti-CTLA-4 therapy - - Preliminary survival analysis of ADG126 10 mg/kg dosing regimens in patients without liver and peritoneal metastases indicates best-in-class median progression-free survival (PFS) of seven months - - Data from additional patients at 10 mg/kg Q3W dosing regimen expected throughout 2024 - SAN DIEGO and SUZHOU, China, Jan. 17, 2024 /PRNewswire/ -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced data from its presentation at the American Society of Clinical Oncology (ASCO) 2024 Gastrointestinal (GI) Cancers Symposium, taking place January 18-20 in San Francisco. "The expanded therapeutic index for the masked ADG126 allows us to dose with a higher and more frequent effective dose of anti-CTLA-4 therapy than today's options," said Daneng Li, MD and Associate Professor Department of Medical Oncology & Therapeutics Research at the City of Hope Comprehensive Cancer Center. "These promising data support further evaluation of this potential best-in-class anti-CTLA-4 antibody, ADG126, in combination with pembrolizumab for MSS CRC patients, including battling new liver lesions in those patients initially without detectable liver metastasis. We also see a tremendous opportunity to help patients in other tumor types where there is a significant need for safe and potent anti-CTLA-4 therapy." Key highlights from the poster (November 30, 2023 data cutoff) include: Results from dose escalation and dose expansion cohorts of ADG126 in combination with Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) (200 mg/Q3W) demonstrated a best-in-class safety profile for ADG126 at doses from 6 mg/kg to 10 mg/kg in heavily pre-treated advanced/metastatic patients (N=46): - Limited dose-dependent toxicities were observed. - Grade 3 TRAEs occurred in 5/46 patients (10.8%), with no Grade 4 or 5 TRAEs and a discontinuation rate of 6.5% (3/46). In dose escalation across tumor types, two partial confirmed responses (PRs) were observed among the three patients treated with ADG126 10 mg/kg Q3W, which triggered expansion cohorts at this dosing regimen. One of the patients had PD-1 refractory cervical cancer and the other had endometrial cancer. Both confirmed PRs are sustained after more than 55 weeks (over 14 cycles) of treatment. In dose expansion of patients with MSS CRC, 12 evaluable patients without liver metastases were treated at the active, potent dose of 10 mg/kg Q3W: - Two confirmed PRs were observed in nine of these patients without peritoneal and liver metastases, resulting in an overall response rate of 22% in this subset. - An additional seven of these nine patients experienced stable disease (SD) for an overall disease control rate 100% (2 PRs and 7 SD). - Observation of these clinical activities triggered further expansion into Stage 2 of the Simon's 2-stage design for this dose level, which is currently ongoing with data anticipated throughout 2024. In a preliminary PFS analysis of those MSS CRC patients free of liver and peritoneal metastasis, a median PFS of seven months was observed in those treated with ADG126 10 mg/kg at two dosing frequencies pooled together [every three weeks (n=9) and every six weeks (n=6)]. The durable clinical activity of ADG126 in combination with pembrolizumab will continue to be evaluated as a larger cohort of subjects becomes evaluable at the 10 mg/kg Q3W dose level. Commenting on the results, Heinz Josef-Lenz, MD, FACP, Associate Director for Clinical Research and Co-leader of the Translational Science Program at the USC Norris Comprehensive Cancer Center (NCCC) said, "I believe that CTLA-4 is an essential part of an effective immunotherapy for MSS CRC, yet physicians have been limited by the safety challenges from first generation options. The clinical profile of ADG126 in combination with pembrolizumab presents a great opportunity for MSS CRC patients that otherwise have limited immunotherapy options available." ASCO-GI Poster Presentation Details Title: Results of a phase 1b/2 study of ADG126 (a masked anti-CTLA-4 SAFEbody) in combo with pembrolizumab (Pembro) in patients (Pts) with metastatic microsatellite-stable (MSS) colorectal cancer (CRC) Date: Saturday, January 20 Time: 6:30 a.m. – 7:55 a.m. Pacific Time Onsite Location: Moscone West Abstract Number: 127 Poster Board: H12